Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
Recruiting now
Conditions studied: Cancer Related Cardiovascular Toxicity
In brief
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
Key facts
- Study ID
- NCT06086132
- Run by
- University of Bologna
- People needed
- 10000
- Starts
- 2025-05-01
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-06-19
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age 18 years old or older
- Capable of giving informed consent
- Diagnosis of cancer scheduled for treatment according to treating physician's discretion
- Life expectancy >1 year
- For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
You may not qualify if…
- Age <18 years old
- Not able to give informed consent
- Life expectancy <1 year
- Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
Where it is running
- Ss. Cyril and Methodius University in Skopje, University Clinic — Skopje, North Macedonia (enrolling)
- University of Belgrade, Clinical Center of Serbia — Belgrade, Serbia (enrolling)
- University of Belgrade, Clinical Hospital Center Bezanijska kosa — Belgrade, Serbia (enrolling)
- University of Bologna — Bologna, Italy
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" — Palermo, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.